Home › NDC Lookup › RxCUI directory › RxCUI 1482821

Gabapentin enacarbil 300 MG Extended Release Oral Tablet [Horizant] — RxCUI 1482821

RxNorm drug concept · Semantic branded drug
RxCUI 1482821 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1482821
Official nameGabapentin enacarbil 300 MG Extended Release Oral Tablet [Horizant]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asHorizant (as gabapentin enacarbil) 300 MG Extended Release Oral Tablet; Horizant 300 MG Extended Release Oral Tablet
FDA products mapped2
Package NDCs mapped4
Reported Medicaid activity (SDUD)7,573 prescriptions · 29 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Gabapentin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Gabapentin is mainly used for two things: managing nerve pain that lingers after a shingles infection (called postherpetic neuralgia) in adults, and helping control partial onset s...
  • This is a really important question. Taking gabapentin together with opioids like morphine, hydrocodone, or oxycodone significantly raises the risk of serious breathing problems —...
  • Can I take gabapentin with my opioid pain medication?
  • The most common ones — especially in the first few weeks — are dizziness, drowsiness, and sometimes loss of balance or coordination. Swelling in the feet or hands is also fairly co...
📖 Read our full Gabapentin guide →

🕸️ Concept Web — How Gabapentin enacarbil 300 MG Extended Release Ora... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Gabapentin enacarbil 300 MG Extended Release Oral Tablet [Horizant] RxCUI 1482821

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Gabapentin 25480
    • Gabapentin enacarbil 1101333
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Horizant 1095698
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Gabapentin Extended Release Oral Tablet 1087974
    • Gabapentin enacarbil Extended Release Oral Tablet 2646304
    • Gabapentin Oral Product 1156681
    • Gabapentin Pill 1156682
    • Gabapentin enacarbil Oral Product 2661340
    • Gabapentin enacarbil Pill 2661177
    • Gabapentin Extended Release Oral Tablet [Horizant] 1095700
    • Gabapentin enacarbil Extended Release Oral Tablet [Horizant] 2657309
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Gabapentin enacarbil 300 MG Extended Release Oral Tablet SCD · 1482820
  • Gabapentin enacarbil 300 MG SCDC · 1482816
  • Gabapentin Extended Release Oral Tablet SCDF · 1087974
  • Gabapentin enacarbil Extended Release Oral Tablet SCDFP · 2646304
  • Gabapentin Oral Product SCDG · 1156681
  • Gabapentin Pill SCDG · 1156682
  • Gabapentin enacarbil Oral Product SCDGP · 2661340
  • Gabapentin enacarbil Pill SCDGP · 2661177

Brand-Name Concepts

  • Gabapentin enacarbil 300 MG [Horizant] SBDC · 1482818
  • Gabapentin Extended Release Oral Tablet [Horizant] SBDF · 1095700
  • Gabapentin enacarbil Extended Release Oral Tablet [Horizant] SBDFP · 2657309
  • Horizant Oral Product SBDG · 1171284
  • Horizant Pill SBDG · 1171285
  • Horizant BN · 1095698

📦 FDA Products & Package NDCs

2 products · 4 package NDCs
4 package NDCs map to RxCUI 1482821 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
53451-0101-01 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (53451-0101... Horizant Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) 2013-05-01
53451-0101-09 5 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (53451-0101-... Horizant Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) 2013-05-01
53451-0103-01 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (53451-0103... Horizant Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) 2013-05-01
53451-0103-09 5 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (53451-0103-... Horizant Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) 2013-05-01
Observed labelers: Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.